Todd Covey

3.3k total citations
33 papers, 1.4k citations indexed

About

Todd Covey is a scholar working on Genetics, Molecular Biology and Hematology. According to data from OpenAlex, Todd Covey has authored 33 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 12 papers in Molecular Biology and 12 papers in Hematology. Recurrent topics in Todd Covey's work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (11 papers) and Acute Myeloid Leukemia Research (7 papers). Todd Covey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (11 papers) and Acute Myeloid Leukemia Research (7 papers). Todd Covey collaborates with scholars based in United States, United Kingdom and Canada. Todd Covey's co-authors include Michael Gulrajani, Hiroki Yoshida, Allard Kaptein, Raquel Izumi, Chris Saris, Fanny Krantz, Giorgio Senaldi, Min Xia, Bas van de Kar and Hiroshi Nishina and has published in prestigious journals such as Blood, Immunity and The Journal of Immunology.

In The Last Decade

Todd Covey

31 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Todd Covey United States 14 663 556 487 318 301 33 1.4k
Mary Stenson United States 23 882 1.3× 502 0.9× 884 1.8× 677 2.1× 743 2.5× 44 2.2k
Georgios Z. Rassidakis United States 17 234 0.4× 207 0.4× 375 0.8× 489 1.5× 414 1.4× 34 1.0k
Mònica López‐Guerra Spain 21 255 0.4× 481 0.9× 393 0.8× 737 2.3× 331 1.1× 61 1.3k
S.A. Johnson United Kingdom 21 716 1.1× 774 1.4× 587 1.2× 411 1.3× 456 1.5× 35 2.0k
Fanny Baran‐Marszak France 20 440 0.7× 435 0.8× 437 0.9× 428 1.3× 467 1.6× 45 1.2k
Stanley Frankel United States 13 196 0.3× 240 0.4× 362 0.7× 514 1.6× 424 1.4× 24 1.2k
Ryouichi Horie Japan 25 929 1.4× 171 0.3× 700 1.4× 599 1.9× 565 1.9× 73 2.0k
Elaine J. Schattner United States 19 1.1k 1.6× 539 1.0× 565 1.2× 497 1.6× 665 2.2× 31 2.0k
Yoshihiro Kameoka Japan 17 220 0.3× 270 0.5× 236 0.5× 563 1.8× 330 1.1× 64 1.3k
Surinder S. Sahota United Kingdom 23 781 1.2× 787 1.4× 708 1.5× 606 1.9× 497 1.7× 61 1.9k

Countries citing papers authored by Todd Covey

Since Specialization
Citations

This map shows the geographic impact of Todd Covey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd Covey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd Covey more than expected).

Fields of papers citing papers by Todd Covey

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd Covey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd Covey. The network helps show where Todd Covey may publish in the future.

Co-authorship network of co-authors of Todd Covey

This figure shows the co-authorship network connecting the top 25 collaborators of Todd Covey. A scholar is included among the top collaborators of Todd Covey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd Covey. Todd Covey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gulrajani, Michael, Jean Cheung, Fanny Krantz, et al.. (2023). P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF). HemaSphere. 7(S3). e41702a0–e41702a0. 1 indexed citations
2.
Nimmagadda, Subbaiah Chary, Todd Covey, Cecile M. Krejsa, et al.. (2023). Navtemadlin, a Novel MDM2 Inhibitor, Potentiated Venetoclax-Induced Antitumor Efficacy in TP53 Wild-Type Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 2782–2782. 1 indexed citations
3.
Cheung, Jean, Michael Gulrajani, Erika M. Gaglione, et al.. (2020). Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib. Clinical Cancer Research. 26(12). 2800–2809. 21 indexed citations
4.
Bruin, Gerjan de, Dennis Demont, Edwin de Zwart, et al.. (2020). Discovery of quinoline-based irreversible BTK inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(14). 127261–127261. 7 indexed citations
5.
Kaptein, Allard, Gerjan de Bruin, Bas van de Kar, et al.. (2018). Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. Blood. 132(Supplement 1). 1871–1871. 71 indexed citations
6.
Niemann, Carsten Utoft, Helena Mora-Jensen, Eman L. Dadashian, et al.. (2017). Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical Cancer Research. 23(19). 5814–5823. 25 indexed citations
7.
Barf, Tjeerd, Todd Covey, Raquel Izumi, et al.. (2017). Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics. 363(2). 240–252. 272 indexed citations
8.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841. 121 indexed citations
9.
Harrington, Bonnie K., Heather L. Gardner, Raquel Izumi, et al.. (2016). Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma. PLoS ONE. 11(7). e0159607–e0159607. 43 indexed citations
10.
Mora-Jensen, Helena, Carsten Utoft Niemann, Michael Gulrajani, et al.. (2016). Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model. Cancer Research. 76(14_Supplement). 4797–4797. 1 indexed citations
11.
Covey, Todd, Tjeerd Barf, Michael Gulrajani, et al.. (2015). Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Research. 75(15_Supplement). 2596–2596. 36 indexed citations
12.
Covey, Todd, Manish Vira, Michael Gulrajani, et al.. (2013). Single cell network profiling assay in bladder cancer. Cytometry Part A. 83A(4). 386–395. 2 indexed citations
13.
Kornblau, Steven M., Mark D. Minden, David B. Rosen, et al.. (2010). Dynamic Single-Cell Network Profiles in Acute Myelogenous Leukemia Are Associated with Patient Response to Standard Induction Therapy. Clinical Cancer Research. 16(14). 3721–3733. 46 indexed citations
14.
Covey, Todd, Santosh Putta, & Alessandra Cesano. (2010). Single Cell Network Profiling (SCNP): Mapping Drug and Target Interactions. Assay and Drug Development Technologies. 8(3). 320–338. 7 indexed citations
15.
Rosen, David B., Santosh Putta, Todd Covey, et al.. (2010). Distinct Patterns of DNA Damage Response and Apoptosis Correlate with Jak/Stat and PI3Kinase Response Profiles in Human Acute Myelogenous Leukemia. PLoS ONE. 5(8). e12405–e12405. 24 indexed citations
16.
Covey, Todd & Alessandra Cesano. (2010). Modulated multiparametric phosphoflow cytometry in hematological malignancies: technology and clinical applications. Best Practice & Research Clinical Haematology. 23(3). 319–331. 11 indexed citations
17.
Covey, Todd, Alessandra Cesano, & David Parkinson. (2010). Single-cell network profiling (SCNP) by flow cytometry in autoimmune disease. Autoimmunity. 43(7). 550–559. 9 indexed citations
18.
Kornblau, Steven M., M.D. Minden, David B. Rosen, et al.. (2009). Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy.. Blood. 114(22). 1582–1582. 1 indexed citations
19.
Artis, David, Alejandro V. Villarino, Michael A. Silverman, et al.. (2004). The IL-27 Receptor (WSX-1) Is an Inhibitor of Innate and Adaptive Elements of Type 2 Immunity. The Journal of Immunology. 173(9). 5626–5634. 203 indexed citations
20.
Yoshida, Hiroki, Shinjiro Hamano, Giorgio Senaldi, et al.. (2001). WSX-1 Is Required for the Initiation of Th1 Responses and Resistance to L. major Infection. Immunity. 15(4). 569–578. 352 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mary Stenson Breakdown of academic impact, for papers by Georgios Z. Rassidakis Breakdown of academic impact, for papers by Mònica López‐Guerra Breakdown of academic impact, for papers by S.A. Johnson Breakdown of academic impact, for papers by Fanny Baran‐Marszak Breakdown of academic impact, for papers by Stanley Frankel Breakdown of academic impact, for papers by Ryouichi Horie Breakdown of academic impact, for papers by Elaine J. Schattner Breakdown of academic impact, for papers by Yoshihiro Kameoka Breakdown of academic impact, for papers by Surinder S. Sahota
Rankless by CCL
2026